Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies

Full text
Pires Borges, Isabela Bruna [1] ; Shinjo, Samuel Katsuyuki [1]
Total Authors: 2
[1] Univ Sao Paulo, Fac Med FMUSP, Div Rheumatol, Sao Paulo, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: RHEUMATOLOGY INTERNATIONAL; v. 39, n. 2, p. 311-316, FEB 2019.
Web of Science Citations: 0

Recent studies have shown a high prevalence of dyslipidemia in patients with systemic autoimmune myopathies (SAM). However, little is known about the safety of the use of statins in these patients, and this gap in research motivated the accomplishment of the present study. In a retrospective cohort study conducted from 2004 to 2018, 250 patients with SAM were evaluated, and 24 patients had stable forms of SAM (16 dermatomyositis, 1 polymyositis and 7 antisynthetase syndrome) but had dyslipidemia and had received statins. Patients with clinically amyopathic dermatomyositis, immune-mediated necrotizing myopathy, dermatomyositis, or polymyositis induced by statins were excluded. The mean age of the patients was 50.6years, and they were predominantly women. The median duration of the disease was 5.0years. Twelve patients received simvastatin (10-60 mg/day), and 11 patients received atorvastatin (20-40 mg/day), and 1 patient received atorvastatin (10 mg/day) which was later replaced by simvastatin (20 mg/day). The median time of exposure to the statin was 22.5months. The follow-up appointments showed that the patients' lipid profiles had improved and that there had been no recurrences of disease activity or clinical intercurrences. Despite the small sampling, the data showed that the use of statins in patients with SAM was safe. New studies with a larger sample and patients with different degrees of disease activity are necessary to corroborate the results of the present study. (AU)

FAPESP's process: 15/12628-0 - Characterization of autoantibody anti-melanoma differentiation associated gene 5 (anti-MDA5) in patients with dermatomyositis and polymyositis
Grantee:Isabela Bruna Pires Borges
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 16/20371-1 - Effect of lipid-lowering drugs on endothelial function and vascular stiffness in patients with dermatomyositis and polymyositis: a prospective, double-blind, randomized controlled trial
Grantee:Isabela Bruna Pires Borges
Support type: Scholarships in Brazil - Master